托法替布对活动性强直性脊柱炎患者疼痛、疲劳、健康相关生活质量和工作生产力的影响:一项III期、随机、双盲、安慰剂对照试验的结果
这项III期随机双盲安慰剂对照试验评估托法替布5 mg每日两次对活动性强直性脊柱炎患者患者报告结局的影响。269例随机治疗患者中,第16周托法替布较安慰剂在BASDAI总体脊柱疼痛、BASDAI疲劳、ASQoL和WPAI总体工作损害方面均显示更大改善(均p<0.001),改善持续至第48周。
要点
- 第16周托法替布较安慰剂显著改善BASDAI总体脊柱疼痛、疲劳、ASQoL和工作损害(均p<0.001)。
- 托法替布组第2周即见脊柱疼痛改善,临床有意义的PRO改善在第16周出现并持续至第48周。
- 第16周托法替布组SF-36v2躯体成分总结、躯体功能及躯体疼痛领域达到≥常模值的比例更高(p≤0.05)。
核心结论
- 在强直性脊柱炎患者中,托法替布5 mg每日两次治疗至第16周在疼痛、疲劳、健康相关生活质量和工作生产力方面较安慰剂产生临床有意义的改善,并持续至第48周。
研究设计与样本
- III期、随机、双盲、安慰剂对照试验;成人强直性脊柱炎患者,对≥2种非甾体抗炎药应答不足或不耐受。
- 患者接受托法替布5 mg每日两次或安慰剂治疗16周,之后所有患者接受开放标签托法替布至第48周。
- 共269例随机并治疗的患者;评估从基线至第48周的患者报告结局变化。
主要发现
- 第16周,托法替布5 mg每日两次 versus 安慰剂的最小二乘均值改善:BASDAI总体脊柱疼痛-2.85 vs -1.34,BASDAI疲劳-2.36 vs -1.08,ASQoL -4.03 vs -2.01,WPAI总体工作损害-21.49 vs -7.64(均p<0.001)。
- 上述改善持续或增加至第48周;托法替布组脊柱疼痛改善在第2周即出现。
- 第16周,托法替布组报告临床有意义的PRO改善的患者比例更高;SF-36v2躯体成分总结、躯体功能及躯体疼痛领域达到≥常模值的比例在托法替布组更高(p≤0.05)。
关键数值与推荐
- BASDAI总体脊柱疼痛第16周较基线最小二乘均值变化:托法替布组-2.85 vs 安慰剂组-1.34(p<0.001)。
- BASDAI疲劳第16周较基线最小二乘均值变化:托法替布组-2.36 vs 安慰剂组-1.08(p<0.001)。
- ASQoL第16周较基线最小二乘均值变化:托法替布组-4.03 vs 安慰剂组-2.01(p<0.001)。
- WPAI总体工作损害第16周较基线最小二乘均值变化:托法替布组-21.49 vs 安慰剂组-7.64(p<0.001)。
- 第16周SF-36v2躯体成分总结、躯体功能及躯体疼痛领域达到≥常模值的比例托法替布组更高(p≤0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ankylosing spondylitis (AS) impacts quality of life. We assessed patient-reported outcomes (PROs), pain, fatigue, health-related quality of life (HRQoL) and work productivity in a phase III trial of tofacitinib. METHODS: Adults with AS and with inadequate response/intolerance to ≥2 non-steroidal anti-inflammatory drugs received tofacitinib 5 mg twice daily or placebo for 16 weeks. Afterwards, all received open-label tofacitinib until week 48. Change from baseline to week 48 was determined for PROs: total back pain; nocturnal spinal pain; Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) overall spinal pain (Q2); Functional Assessment of Chronic Illness Therapy-Fatigue; BASDAI fatigue (Q1); AS Quality of Life (ASQoL); Short Form-36 Health Survey Version 2 (SF-36v2); EuroQoL-Five Dimension-Three Level health profile and Visual Analogue Scale; and the Work Productivity and Activity Impairment (WPAI) questionnaire. Improvements from baseline ≥minimum clinically important difference, and scores ≥normative values at week 16 were evaluated. RESULTS: In 269 randomised and treated patients, at week 16, there were greater least squares mean improvements from baseline with tofacitinib 5 mg twice daily versus placebo in BASDAI overall spinal pain (-2.85 vs -1.34), BASDAI fatigue (-2.36 vs -1.08), ASQoL (-4.03 vs -2.01) and WPAI overall work impairment (-21.49 vs -7.64) (all p<0.001); improvements continued/increased to week 48. Improved spinal pain with tofacitinib was seen by week 2. Patients receiving tofacitinib reported clinically meaningful PRO improvements at week 16. Percentages with PRO scores ≥normative values at week 16 were greater with tofacitinib in SF-36v2 Physical Component Summary, physical functioning and bodily pain domains (p≤0.05). CONCLUSIONS: In patients with AS, treatment with tofacitinib 5 mg twice daily resulted in clinically meaningful improvements in pain, fatigue, HRQoL and work productivity versus placebo to week 16, which were sustained to week 48. TRIAL REGISTRATION NUMBER: NCT03502616.
引用
- Navarro-Compán V, Wei JC, Van den Bosch F, et al. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022. PMID: 35654457. doi:10.1136/rmdopen-2022-002253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。